Sublime
An inspiration engine for ideas
Having some fun with the numbers behind $NVS's recent $87.5M acquisition of $AVRO's Cystinosis LVV gene therapy program... (1/6)
Professor Oakx.comGenAI Ventures
@cosmos
Predictions of What We Expect in 2024 in M&A
pharmas expected to have “high” or “very high” M&A appetite in 2024.
M&A interest is expected to be highest in cardiometabolic disease, immunology, oncology, genetic disease and neurologic diseases.
From Stifel
wowowow $XBI https://t.co/GKEQ5oi9CW
Where Biology Goes Off the Rails - Dr. Michael Levin, @drmichaellevin Cool stuff!! #Biology #bioengineering #Regenerative #Medicine DemystifySci #369 https://t.co/SPQ3b0JljG via @YouTube
Sheila Macrine, Ph.D.x.com
List of approved Gene Therapies
**best selling is ZOLGENSMA w/ 2021 ~$1.4B Revs https://t.co/fsNh706DHv
Martin Gonella
@mgonella
Marc Eglon
@marceglon
Maja Shapiro
@marionjoyce